PLAU and esophageal cancer: The expression of uPA and its receptor uPAR were increased significantly in breast cancer, ovarian cancer, gastric cancer, esophageal cancer, lung cancer, liver cancer, colon cancer, prostate cancer and bile duct cancer [11–17].